Shimadzu, Ceres Nanosciences and Nonlinear Dynamics Introduce Nanotrap™ Biomarker Discovery Platform

16 Mar 2010
Sarah Sarah
Marketing / Sales

Product news

Shimadzu Scientific Instruments has partnered with Ceres Nanosciences and Nonlinear Dynamics to bring the future of biomarker discovery to laboratory researchers. The Nanotrap™ Biomarker Discovery Platform gives researchers the ability to enrich, preserve and screen low-level biomarkers directly from complex biological samples.

Nanotraps are core shell hydrogel particles with porous interiors and size exclusion shells. By delivering affinity selection and size exclusion in one step, Shimadzu’s Nanotrap Biomarker Discovery Platform easily amplifies low-level biomarkers directly from complex biological fluids. This enables the harvesting of low-abundance biomarkers directly from complex samples, making early disease detection possible.

Biomarkers in current clinical use have low sensitivity and specificity, and limited use for early disease detection. Nanotraps meet this challenge by providing fractionation, concentration and protection of low-level biomarkers directly from complex biological fluids.

Integrating Nanotraps with AXIMA MALDI mass spectrometry for screening and identification provides researchers these benefits:

• Enriched and concentrated low-abundance proteins from complex bio-fluid samples
• Prevents protein degradation during sample processing
• Decrease amount of high-abundance proteins present in samples
• Does not require antibodies for immunodepletion or immunoprecipitation
• Simple format and quick sample processing technique
• Fully-integrated informatics capabilities (Progenesis MALDI, Nonlinear Dynamics)
• Simplified screening and identification for biomarker discovery and validation

When used with the AXIMA MALDI mass spectrometers, Nanotrap-enriched samples are analyzed rapidly and reproducibly in a fully automated format. Additionally, disposable Fleximass-DS targets are available for contamination-free analysis and sample archiving.

Progenesis MALDI, the software component of the Nanotrap Biomarker Discovery Platform, generates high-quality proteomics data to define biomarkers. It uses the unique Progenesis approach and technology to improve the reliability and reproducibility of results, and it adds speed, objectivity and statistics to biomarker discovery.

Links

Tags

Mass SpectrometryMass spectrometry (MS) is a powerful analytical technique used to identify and quantify molecules based on the mass-to-charge ratio of gas-phase ions. It provides detailed information about the structure, composition, and properties of compounds and is widely used across fields such as environmental monitoring, materials science, drug discovery and development, food and beverage testing, and wider chemical research. Key MS techniques include tandem mass spectrometry (MS/MS), liquid chromatography–mass spectrometry (LS-MS) and inductively coupled plasma (ICP-MS). Choosing from these wide range of techniques and technologies can be a daunting task, so keep up to date with scientific applications, performance expectations, and customer reviews here all in one place. Visit our product directory to receive quotes direct from the manufacturer. Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.NanotechnologyNanotechnology, or nanotech, is an engineering technique using molecular scale functional systems. Applications of nanotechnology include medicine and medical devices, electronics, air and water purification, food science and energy production.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.
Shimadzu, Ceres Nanosciences and Nonlinear Dynamics Introduce Nanotrap™ Biomarker Discovery Platform